Ranitidine versus ranitidine plus octreotide in the treatment of acute non-variceal upper gastrointestinal bleeding: a prospective randomised study. 2000

A Archimandritis, and M Tsirantonaki, and M Tryphonos, and D Kourtesas, and S Sougioultzis, and A Papageorgiou, and M Tzivras
Department of Pathophysiology, Gastroenterology Section, University of Athens Medical School, Laikon General Hospital, Athens, Greece. aarchim@cc.uoa.gr

OBJECTIVE To compare the efficacy of ranitidine with that of ranitidine plus octreotide in the treatment of non-variceal upper gastrointestinal (UGI) bleeding. METHODS Prospective, randomised, open study. METHODS Upper GI endoscopy was carried out during the first 24 hours in all patients with UGI bleeding who had been admitted within a period of 18 months. Patients with variceal bleeding, and those who had undergone any type of gastric operation, were excluded. Eighty-four patients (58 men and 26 women) aged 21-92 years (mean age: 61.2 +/- 15.0 SD) were included. Patients were randomised to receive ranitidine 50 mg tid intravenously alone (Group A: 44 patients, 29 men), or in combination with octreotide 100 micrograms tid subcutaneously, the second drug given for three days only (Group B: 40 patients, 29 men). The study end-points were discharge without operation, emergency surgical intervention or death. The number of blood units given and the days of hospitalization were also recorded. RESULTS Aspirin and non-aspirin NSAID use before bleeding was reported by 16/44 (36%) patients in Group A and by 19/40 (47.5%) patients in Group B (p = 0.38, OR = 0.63, 95% CI = 0.26-1.51). The endoscopically detected pathology and bleeding stigmata did not differ between the groups (p = 0.86, p = 0.64, OR = 0.78, 95% CI = 0.3-1.99, respectively). Mean use of blood units (p = 0.16) and days of hospitalization (p = 0.25) did not differ. Three patients in Group A (6.8%) and three in Group B (7.5%) required surgical intervention (p = 1.0, OR = 1.1, 95% CI = 0.21-5.84). CONCLUSIONS Ranitidine plus subcutaneous octreotide is not superior to ranitidine alone in the management of patients with acute non-variceal UGI bleeding.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D011899 Ranitidine A non-imidazole blocker of those histamine receptors that mediate gastric secretion (H2 receptors). It is used to treat gastrointestinal ulcers. AH-19065,Biotidin,N (2-(((5-((Dimethylamino)methyl)-2-furanyl)methyl)thio)ethyl)-N'-methyl-2-nitro-1,1-ethenediamine,Ranisen,Ranitidin,Ranitidine Hydrochloride,Sostril,Zantac,Zantic,AH 19065,AH19065,Hydrochloride, Ranitidine
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005260 Female Females
D005765 Gastrointestinal Agents Drugs used for their effects on the gastrointestinal system, as to control gastric acidity, regulate gastrointestinal motility and water flow, and improve digestion. Digestants,Gastric Agents,Gastric Drugs,Gastrointestinal Drugs,Agents, Gastric,Agents, Gastrointestinal,Drugs, Gastric,Drugs, Gastrointestinal
D006471 Gastrointestinal Hemorrhage Bleeding in any segment of the GASTROINTESTINAL TRACT from ESOPHAGUS to RECTUM. Hematochezia,Hemorrhage, Gastrointestinal,Gastrointestinal Hemorrhages,Hematochezias
D006635 Histamine H2 Antagonists Drugs that selectively bind to but do not activate histamine H2 receptors, thereby blocking the actions of histamine. Their clinically most important action is the inhibition of acid secretion in the treatment of gastrointestinal ulcers. Smooth muscle may also be affected. Some drugs in this class have strong effects in the central nervous system, but these actions are not well understood. Antihistaminics, H2,H2 Receptor Blockader,Histamine H2 Antagonist,Histamine H2 Blocker,Histamine H2 Receptor Antagonist,Histamine H2 Receptor Antagonists,Histamine H2 Receptor Blockader,Histamine H2 Receptor Blockaders,Antagonists, Histamine H2,Blockaders, Histamine H2 Receptor,H2 Receptor Blockaders,Histamine H2 Blockers,Receptor Antagonists, Histamine H2,Receptor Blockaders, H2,Antagonist, Histamine H2,Blockader, H2 Receptor,Blockaders, H2 Receptor,Blocker, Histamine H2,Blockers, Histamine H2,H2 Antagonist, Histamine,H2 Antagonists, Histamine,H2 Antihistaminics,H2 Blocker, Histamine,H2 Blockers, Histamine,Receptor Blockader, H2
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

A Archimandritis, and M Tsirantonaki, and M Tryphonos, and D Kourtesas, and S Sougioultzis, and A Papageorgiou, and M Tzivras
January 2000, Hepato-gastroenterology,
A Archimandritis, and M Tsirantonaki, and M Tryphonos, and D Kourtesas, and S Sougioultzis, and A Papageorgiou, and M Tzivras
April 2018, Nature reviews. Disease primers,
A Archimandritis, and M Tsirantonaki, and M Tryphonos, and D Kourtesas, and S Sougioultzis, and A Papageorgiou, and M Tzivras
January 2006, The Ulster medical journal,
A Archimandritis, and M Tsirantonaki, and M Tryphonos, and D Kourtesas, and S Sougioultzis, and A Papageorgiou, and M Tzivras
February 2001, Best practice & research. Clinical gastroenterology,
A Archimandritis, and M Tsirantonaki, and M Tryphonos, and D Kourtesas, and S Sougioultzis, and A Papageorgiou, and M Tzivras
April 2022, Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract,
A Archimandritis, and M Tsirantonaki, and M Tryphonos, and D Kourtesas, and S Sougioultzis, and A Papageorgiou, and M Tzivras
April 2002, Minerva medica,
A Archimandritis, and M Tsirantonaki, and M Tryphonos, and D Kourtesas, and S Sougioultzis, and A Papageorgiou, and M Tzivras
June 2000, Bailliere's best practice & research. Clinical gastroenterology,
A Archimandritis, and M Tsirantonaki, and M Tryphonos, and D Kourtesas, and S Sougioultzis, and A Papageorgiou, and M Tzivras
February 2005, Postgraduate medical journal,
A Archimandritis, and M Tsirantonaki, and M Tryphonos, and D Kourtesas, and S Sougioultzis, and A Papageorgiou, and M Tzivras
April 1985, Connecticut medicine,
A Archimandritis, and M Tsirantonaki, and M Tryphonos, and D Kourtesas, and S Sougioultzis, and A Papageorgiou, and M Tzivras
October 2013, Postgraduate medical journal,
Copied contents to your clipboard!